Emergent Biosolutions Inc. (NYSE:EBS)’s share price reached a new 52-week low during trading on Wednesday . The stock traded as low as $26.14 and last traded at $26.28, with a volume of 121,711 shares changing hands. The stock had previously closed at $27.06.

Several equities analysts have recently commented on EBS shares. Singular Research lowered their price target on shares of Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, June 28th. Wells Fargo & Co. restated a “buy” rating on shares of Emergent Biosolutions in a report on Wednesday, June 22nd. Cowen and Company restated a “hold” rating and set a $33.00 price target on shares of Emergent Biosolutions in a report on Sunday, August 7th. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “sell” rating to a “hold” rating in a report on Monday, July 4th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating on the stock in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $40.00.

The stock has a 50 day moving average price of $29.50 and a 200 day moving average price of $35.21. The firm has a market capitalization of $1.07 billion and a PE ratio of 18.89.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. During the same quarter in the prior year, the firm earned $0.36 EPS. The business had revenue of $101.49 million for the quarter, compared to analysts’ expectations of $111.20 million. The company’s revenue was down 19.5% on a year-over-year basis. On average, equities analysts anticipate that Emergent Biosolutions Inc. will post $1.03 EPS for the current fiscal year.

In other Emergent Biosolutions news, Director George A. Joulwan sold 4,700 shares of Emergent Biosolutions stock in a transaction on Monday, June 6th. The shares were sold at an average price of $44.12, for a total value of $207,364.00. Following the sale, the director now directly owns 20,785 shares in the company, valued at approximately $917,034.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.